Literature DB >> 3567927

Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells.

N Shiraishi, S Akiyama, M Nakagawa, M Kobayashi, M Kuwano.   

Abstract

Cepharanthine, a bisbenzylisoquinoline (biscoclaurine) alkaloid, completely overcomes resistance of a multidrug-resistant subline, ChR-24, derived from human KB carcinoma cells, to vincristine, actinomycin D, and daunomycin, and partially overcomes resistance to Adriamycin. Another biscoclaurine alkaloid, berbamine, partially overcomes resistance to these anticancer agents. Accumulation of [3H]daunomycin in ChR-24 cells is about 10% of that in both the parental KB and revertant cell line (Rev-2) which is derived from ChR-24. Cepharanthine prominently increases the accumulation of daunomycin in resistant ChR-24 cells, but not in parental KB and Rev-2 cells. Enhanced efflux of daunomycin from the resistant cells is completely inhibited by cepharanthine. Cellular uptake of [3H]daunomycin is not significantly affected in the resistant cells by cepharanthine. Accumulation of [3H]cepharanthine is observed at similar levels in both KB and ChR-24. Phosphatidylserine specifically inhibited the accumulation of [3H]cepharanthine in KB and ChR-24 cells when tested by adding various phospholipids such as phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin to culture medium. The enhanced accumulation of [3H]daunomycin in cepharanthine-treated ChR-24 cells is inhibited in the presence of 20 micrograms/ml phosphatidylserine. Cepharanthine may overcome multidrug resistance by binding to phosphatidylserine in the plasma membrane and perturbing membrane function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567927

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Inhibition of the STAT3 signaling pathway is involved in the antitumor activity of cepharanthine in SaOS2 cells.

Authors:  Zan Chen; Chen Huang; Yan-ling Yang; Yi Ding; Han-qiang Ou-Yang; You-yi Zhang; Ming Xu
Journal:  Acta Pharmacol Sin       Date:  2012-01       Impact factor: 6.150

2.  Cepharanthine exerts antitumor activity on choroidal melanoma by reactive oxygen species production and c-Jun N-terminal kinase activation.

Authors:  Qi Zhu; Baofeng Guo; Linlin Chen; Qiuye Ji; Hang Liang; Naiyan Wen; Ling Zhang
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

3.  Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.

Authors:  Rishil J Kathawala; Kamlesh Sodani; Kang Chen; Atish Patel; Alaa H Abuznait; Nagaraju Anreddy; Yue-Li Sun; Amal Kaddoumi; Charles R Ashby; Zhe-Sheng Chen
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

4.  Non-glucocorticoid steroid analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine.

Authors:  I Abraham; C L Wolf; K E Sampson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.

Authors:  L S Borman; W G Bornmann; M E Kuehne
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

7.  Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability.

Authors:  I K Pajeva; M Wiese; H P Cordes; J K Seydel
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Positive interactions between human interferon and cepharanthin against human cancer cells in vitro and in vivo.

Authors:  M Ono; N Tanaka; K Orita
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 9.  Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs.

Authors:  Sharna-Kay Daley; Geoffrey A Cordell
Journal:  Molecules       Date:  2021-06-22       Impact factor: 4.411

10.  Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.

Authors:  M Sehested; T Skovsgaard; P B Jensen; E J Demant; E Friche; N Bindslev
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.